Published in J Neurosci on September 28, 2005
ApoE-directed therapeutics rapidly clear β-amyloid and reverse deficits in AD mouse models. Science (2012) 10.42
ApoE promotes the proteolytic degradation of Abeta. Neuron (2008) 4.75
Early-onset behavioral and synaptic deficits in a mouse model of Alzheimer's disease. Proc Natl Acad Sci U S A (2006) 3.61
The role of microglia in amyloid clearance from the AD brain. J Neural Transm (Vienna) (2010) 2.21
The benefits and limitations of animal models for translational research in neurodegenerative diseases. Nat Med (2010) 1.86
Critical role of soluble amyloid-β for early hippocampal hyperactivity in a mouse model of Alzheimer's disease. Proc Natl Acad Sci U S A (2012) 1.58
Amygdala-dependent fear memory consolidation via miR-34a and Notch signaling. Neuron (2014) 1.56
Acute inhibition of calcineurin restores associative learning and memory in Tg2576 APP transgenic mice. Neurobiol Learn Mem (2007) 1.50
The glial modulatory drug AV411 attenuates mechanical allodynia in rat models of neuropathic pain. Neuron Glia Biol (2006) 1.43
Notch and transforming growth factor-beta (TGFbeta) signaling pathways cooperatively regulate vascular smooth muscle cell differentiation. J Biol Chem (2010) 1.38
Treatment strategies targeting amyloid β-protein. Cold Spring Harb Perspect Med (2012) 1.37
Selective phosphodiesterase inhibitors: a promising target for cognition enhancement. Psychopharmacology (Berl) (2008) 1.36
Targeting Notch signaling in autoimmune and lymphoproliferative disease. Blood (2007) 1.33
Beta-secretase inhibitor GRL-8234 rescues age-related cognitive decline in APP transgenic mice. FASEB J (2010) 1.29
Enhanced clearance of Abeta in brain by sustaining the plasmin proteolysis cascade. Proc Natl Acad Sci U S A (2008) 1.12
The β-secretase-derived C-terminal fragment of βAPP, C99, but not Aβ, is a key contributor to early intraneuronal lesions in triple-transgenic mouse hippocampus. J Neurosci (2012) 1.11
Existing plaques and neuritic abnormalities in APP:PS1 mice are not affected by administration of the gamma-secretase inhibitor LY-411575. Mol Neurodegener (2009) 1.07
Spines, plasticity, and cognition in Alzheimer's model mice. Neural Plast (2011) 1.06
Targets for AD treatment: conflicting messages from γ-secretase inhibitors. J Neurochem (2011) 1.05
Loss of alpha7 nicotinic receptors enhances beta-amyloid oligomer accumulation, exacerbating early-stage cognitive decline and septohippocampal pathology in a mouse model of Alzheimer's disease. J Neurosci (2010) 1.04
Neuroinflammation and neuronal loss precede Aβ plaque deposition in the hAPP-J20 mouse model of Alzheimer's disease. PLoS One (2013) 1.04
Genetic modulation of soluble Aβ rescues cognitive and synaptic impairment in a mouse model of Alzheimer's disease. J Neurosci (2014) 1.00
GEBR-7b, a novel PDE4D selective inhibitor that improves memory in rodents at non-emetic doses. Br J Pharmacol (2011) 1.00
Inhibition of phosphodiesterase-4 reverses memory deficits produced by Aβ25-35 or Aβ1-40 peptide in rats. Psychopharmacology (Berl) (2010) 0.99
CHF5074, a novel gamma-secretase modulator, attenuates brain beta-amyloid pathology and learning deficit in a mouse model of Alzheimer's disease. Br J Pharmacol (2009) 0.98
Lowering beta-amyloid levels rescues learning and memory in a Down syndrome mouse model. PLoS One (2010) 0.97
Flavonoid-mediated presenilin-1 phosphorylation reduces Alzheimer's disease beta-amyloid production. J Cell Mol Med (2008) 0.97
Reversible pathologic and cognitive phenotypes in an inducible model of Alzheimer-amyloidosis. J Neurosci (2013) 0.95
Inhibition of gamma secretase blocks HPV infection. Virology (2010) 0.94
Structural correlates of antibodies associated with acute reversal of amyloid beta-related behavioral deficits in a mouse model of Alzheimer disease. J Biol Chem (2009) 0.94
Anti-dementia drugs and hippocampal-dependent memory in rodents. Behav Pharmacol (2007) 0.93
SAHA enhances synaptic function and plasticity in vitro but has limited brain availability in vivo and does not impact cognition. PLoS One (2013) 0.91
Amyloid precursor protein selective gamma-secretase inhibitors for treatment of Alzheimer's disease. Alzheimers Res Ther (2010) 0.91
Modulation of γ-secretase by EVP-0015962 reduces amyloid deposition and behavioral deficits in Tg2576 mice. Mol Neurodegener (2012) 0.90
Selective loss of noradrenaline exacerbates early cognitive dysfunction and synaptic deficits in APP/PS1 mice. Biol Psychiatry (2012) 0.90
APP transgenic mice for modelling behavioural and psychological symptoms of dementia (BPSD). Neurosci Biobehav Rev (2012) 0.89
Behavioral assays with mouse models of Alzheimer's disease: practical considerations and guidelines. Biochem Pharmacol (2014) 0.89
Sustained peripheral depletion of amyloid-β with a novel form of neprilysin does not affect central levels of amyloid-β. Brain (2013) 0.88
Prion-Protein-interacting Amyloid-β Oligomers of High Molecular Weight Are Tightly Correlated with Memory Impairment in Multiple Alzheimer Mouse Models. J Biol Chem (2015) 0.88
An update on the amyloid hypothesis. Neurol Clin (2007) 0.87
Galantamine slows down plaque formation and behavioral decline in the 5XFAD mouse model of Alzheimer's disease. PLoS One (2014) 0.86
Consequences of inhibiting amyloid precursor protein processing enzymes on synaptic function and plasticity. Neural Plast (2012) 0.86
Interpreting Alzheimer's disease clinical trials in light of the effects on amyloid-β. Alzheimers Res Ther (2014) 0.85
Modulators of γ-secretase activity can facilitate the toxic side-effects and pathogenesis of Alzheimer's disease. PLoS One (2013) 0.83
Alzheimer's disease and age-related memory decline (preclinical). Pharmacol Biochem Behav (2011) 0.83
Longitudinal brain corticotropin releasing factor and somatostatin in a transgenic mouse (TG2576) model of Alzheimer's disease. J Alzheimers Dis (2007) 0.83
Reduction of β-amyloid deposits by γ-secretase inhibitor is associated with the attenuation of secondary damage in the ipsilateral thalamus and sensory functional improvement after focal cortical infarction in hypertensive rats. J Cereb Blood Flow Metab (2010) 0.82
Hippocampal neurogenesis: Learning to remember. Prog Neurobiol (2016) 0.82
The role of adenosine in Alzheimer's disease. Curr Neuropharmacol (2009) 0.81
NPTX2 and cognitive dysfunction in Alzheimer's Disease. Elife (2017) 0.81
Ear2 deletion causes early memory and learning deficits in APP/PS1 mice. J Neurosci (2014) 0.79
Modulation of γ-secretase activity by multiple enzyme-substrate interactions: implications in pathogenesis of Alzheimer's disease. PLoS One (2012) 0.78
mNos2 deletion and human NOS2 replacement in Alzheimer disease models. J Neuropathol Exp Neurol (2014) 0.78
Mechanisms of neural and behavioral dysfunction in Alzheimer's disease. Mol Neurobiol (2011) 0.78
Longitudinal testing of hippocampal plasticity reveals the onset and maintenance of endogenous human Aß-induced synaptic dysfunction in individual freely behaving pre-plaque transgenic rats: rapid reversal by anti-Aß agents. Acta Neuropathol Commun (2014) 0.77
Amyloid-modifying therapies for Alzheimer's disease: therapeutic progress and its implications. Age (Dordr) (2010) 0.77
Intracellular selection of peptide inhibitors that target disulphide-bridged Aβ42 oligomers. Protein Sci (2014) 0.77
Mouse Genetic Models of Human Brain Disorders. Front Genet (2016) 0.76
Fluid Biomarkers in Clinical Trials of Alzheimer's Disease Therapeutics. Front Neurol (2015) 0.76
Tailoring the antibody response to aggregated Aß using novel Alzheimer-vaccines. PLoS One (2015) 0.76
Familial Alzheimer's disease-associated presenilin 1 mutants promote γ-secretase cleavage of STIM1 to impair store-operated Ca2+ entry. Sci Signal (2016) 0.75
Early-onset behavioral and synaptic deficits in a mouse model of Alzheimer's disease. Proc Natl Acad Sci U S A (2006) 3.61
Rapamycin alleviates toxicity of different aggregate-prone proteins. Hum Mol Genet (2005) 3.45
Loss of retrograde endocannabinoid signaling and reduced adult neurogenesis in diacylglycerol lipase knock-out mice. J Neurosci (2010) 2.78
Phospho-dependent functional modulation of GABA(B) receptors by the metabolic sensor AMP-dependent protein kinase. Neuron (2007) 2.38
Pre-existing renal disease promotes sepsis-induced acute kidney injury and worsens outcome. Kidney Int (2008) 2.37
Activation of estrogen receptor-beta regulates hippocampal synaptic plasticity and improves memory. Nat Neurosci (2008) 2.29
Schizophrenia-related neural and behavioral phenotypes in transgenic mice expressing truncated Disc1. J Neurosci (2008) 2.04
mRNA distribution analysis of human TRPC family in CNS and peripheral tissues. Brain Res Mol Brain Res (2002) 1.98
Impact of apolipoprotein E (ApoE) polymorphism on brain ApoE levels. J Neurosci (2008) 1.92
Functional characterization of Narc 1, a novel proteinase related to proteinase K. Arch Biochem Biophys (2003) 1.88
Abdominal fat is associated with lower bone formation and inferior bone quality in healthy premenopausal women: a transiliac bone biopsy study. J Clin Endocrinol Metab (2013) 1.88
Mendel: the Swiss army knife of genetic analysis programs. Bioinformatics (2013) 1.85
The clustering of GABA(A) receptor subtypes at inhibitory synapses is facilitated via the direct binding of receptor alpha 2 subunits to gephyrin. J Neurosci (2008) 1.83
ADX47273 [S-(4-fluoro-phenyl)-{3-[3-(4-fluoro-phenyl)-[1,2,4]-oxadiazol-5-yl]-piperidin-1-yl}-methanone]: a novel metabotropic glutamate receptor 5-selective positive allosteric modulator with preclinical antipsychotic-like and procognitive activities. J Pharmacol Exp Ther (2008) 1.81
Monoacylglycerol lipase activity is a critical modulator of the tone and integrity of the endocannabinoid system. Mol Pharmacol (2010) 1.81
Contributions of the measles virus nucleocapsid gene and the SQSTM1/p62(P392L) mutation to Paget's disease. Cell Metab (2011) 1.81
A novel tetracycline labeling schedule for longitudinal evaluation of the short-term effects of anabolic therapy with a single iliac crest bone biopsy: early actions of teriparatide. J Bone Miner Res (2005) 1.78
PKA phosphorylation activates the calcium release channel (ryanodine receptor) in skeletal muscle: defective regulation in heart failure. J Cell Biol (2003) 1.78
MRI of the basement membrane using charged nanoparticles as contrast agents. Magn Reson Med (2008) 1.77
Effects of a one-month treatment with PTH(1-34) on bone formation on cancellous, endocortical, and periosteal surfaces of the human ilium. J Bone Miner Res (2007) 1.75
CD147 is a regulatory subunit of the gamma-secretase complex in Alzheimer's disease amyloid beta-peptide production. Proc Natl Acad Sci U S A (2005) 1.73
Rapid isolation of urinary exosomal biomarkers using a nanomembrane ultrafiltration concentrator. Am J Physiol Renal Physiol (2007) 1.72
The LXR agonist TO901317 selectively lowers hippocampal Abeta42 and improves memory in the Tg2576 mouse model of Alzheimer's disease. Mol Cell Neurosci (2007) 1.66
Chloroquine and inhibition of Toll-like receptor 9 protect from sepsis-induced acute kidney injury. Am J Physiol Renal Physiol (2008) 1.59
Phospho-dependent binding of the clathrin AP2 adaptor complex to GABAA receptors regulates the efficacy of inhibitory synaptic transmission. Proc Natl Acad Sci U S A (2005) 1.56
Wide dissemination of OXA-23-producing carbapenem-resistant Acinetobacter baumannii clonal complex 22 in multiple cities of China. J Antimicrob Chemother (2010) 1.56
BACE1 (beta-secretase) transgenic and knockout mice: identification of neurochemical deficits and behavioral changes. Mol Cell Neurosci (2003) 1.52
Mutation of the sequestosome 1 (p62) gene increases osteoclastogenesis but does not induce Paget disease. J Clin Invest (2006) 1.52
Chronic kidney disease worsens sepsis and sepsis-induced acute kidney injury by releasing High Mobility Group Box Protein-1. Kidney Int (2011) 1.52
Begacestat (GSI-953): a novel, selective thiophene sulfonamide inhibitor of amyloid precursor protein gamma-secretase for the treatment of Alzheimer's disease. J Pharmacol Exp Ther (2009) 1.51
Activity-dependent ubiquitination of GABA(A) receptors regulates their accumulation at synaptic sites. J Neurosci (2007) 1.49
Dynamic and structural properties of the skeleton in hypoparathyroidism. J Bone Miner Res (2008) 1.46
Anabolic action of parathyroid hormone is skeletal site specific at the tissue and cellular levels in mice. J Bone Miner Res (2002) 1.44
Isolation and purification of exosomes in urine. Methods Mol Biol (2010) 1.44
Phosphorylation and chronic agonist treatment atypically modulate GABAB receptor cell surface stability. J Biol Chem (2004) 1.40
Left ventricular apical aneurysm associated with normal coronary arteries following cardiac surgery: echocardiographic features and differential diagnosis. Int J Cardiol (2013) 1.39
Skeletal histomorphometry in subjects on teriparatide or zoledronic acid therapy (SHOTZ) study: a randomized controlled trial. J Clin Endocrinol Metab (2012) 1.38
Treatment strategies targeting amyloid β-protein. Cold Spring Harb Perspect Med (2012) 1.37
Squamous cell carcinoma of the head and neck: diffusion-weighted MR imaging for prediction and monitoring of treatment response. Eur Radiol (2010) 1.35
Phosphodiesterase 10A inhibitor activity in preclinical models of the positive, cognitive, and negative symptoms of schizophrenia. J Pharmacol Exp Ther (2009) 1.35
A SQSTM1/p62 mutation linked to Paget's disease increases the osteoclastogenic potential of the bone microenvironment. Hum Mol Genet (2008) 1.33
PTH(1-84) administration reverses abnormal bone-remodeling dynamics and structure in hypoparathyroidism. J Bone Miner Res (2011) 1.30
Evolution of radiation-induced brain injury: MR imaging-based study. Radiology (2009) 1.30
Interleukin-17 cytokines are critical in development of fatal lupus glomerulonephritis. Immunity (2012) 1.30
A diacylglycerol lipase-CB2 cannabinoid pathway regulates adult subventricular zone neurogenesis in an age-dependent manner. Mol Cell Neurosci (2008) 1.30
Missing steps in the STAIR case: a Translational Medicine perspective on the development of NXY-059 for treatment of acute ischemic stroke. J Cereb Blood Flow Metab (2007) 1.26
Binding of rapamycin analogs to calcium channels and FKBP52 contributes to their neuroprotective activities. Proc Natl Acad Sci U S A (2007) 1.23
Discovery of begacestat, a Notch-1-sparing gamma-secretase inhibitor for the treatment of Alzheimer's disease. J Med Chem (2008) 1.22
Expression of measles virus nucleocapsid protein in osteoclasts induces Paget's disease-like bone lesions in mice. J Bone Miner Res (2005) 1.22
Hypoxia-inducible factor-1-mediated regulation of semaphorin 4D affects tumor growth and vascularity. J Biol Chem (2009) 1.20
Use of PCR and reverse line blot hybridization assay for rapid simultaneous detection and serovar identification of Chlamydia trachomatis. J Clin Microbiol (2006) 1.20
Cloning and functional expression of human short TRP7, a candidate protein for store-operated Ca2+ influx. J Biol Chem (2002) 1.19
Genotype imputation via matrix completion. Genome Res (2012) 1.18
Transient myofibroblast differentiation of interstitial fibroblastic cells relevant to tubular dilatation in uranyl acetate-induced acute renal failure in rats. Virchows Arch (2004) 1.18
Methyl-2-acetamidoacrylate, an ethyl pyruvate analog, decreases sepsis-induced acute kidney injury in mice. Am J Physiol Renal Physiol (2008) 1.17
The orphan GPCR, GPR88, modulates function of the striatal dopamine system: a possible therapeutic target for psychiatric disorders? Mol Cell Neurosci (2009) 1.16
Angiotensin II overcomes strain-dependent resistance of rapid CKD progression in a new remnant kidney mouse model. Kidney Int (2010) 1.16
Atomic layer engineering of perovskite oxides for chemically sharp heterointerfaces. Adv Mater (2012) 1.15
Prolonged activation of NMDA receptors promotes dephosphorylation and alters postendocytic sorting of GABAB receptors. Proc Natl Acad Sci U S A (2010) 1.14
Pharmacological comparison of muscarinic ligands: historical versus more recent muscarinic M1-preferring receptor agonists. Eur J Pharmacol (2009) 1.13
MicroRNA-99a induces G1-phase cell cycle arrest and suppresses tumorigenicity in renal cell carcinoma. BMC Cancer (2012) 1.13
Widespread occurrence of aminoglycoside resistance due to ArmA methylase in imipenem-resistant Acinetobacter baumannii isolates in China. J Antimicrob Chemother (2007) 1.13
Myostatin inhibition slows muscle atrophy in rodent models of amyotrophic lateral sclerosis. Neurobiol Dis (2006) 1.12
Three dimensional cancellous bone structure in hypoparathyroidism. Bone (2009) 1.12
Receptor and behavioral pharmacology of WAY-267464, a non-peptide oxytocin receptor agonist. Neuropharmacology (2009) 1.12
Marlin-1, a novel RNA-binding protein associates with GABA receptors. J Biol Chem (2004) 1.12
Wide distribution of CC92 carbapenem-resistant and OXA-23-producing Acinetobacter baumannii in multiple provinces of China. Int J Antimicrob Agents (2013) 1.12
Trabecular bone response to mechanical and parathyroid hormone stimulation: the role of mechanical microenvironment. J Bone Miner Res (2003) 1.12
Enhanced clearance of Abeta in brain by sustaining the plasmin proteolysis cascade. Proc Natl Acad Sci U S A (2008) 1.12
The availability of surface GABA B receptors is independent of gamma-aminobutyric acid but controlled by glutamate in central neurons. J Biol Chem (2008) 1.12
Abnormal bone microarchitecture and evidence of osteoblast dysfunction in premenopausal women with idiopathic osteoporosis. J Clin Endocrinol Metab (2011) 1.11
The structure of the Lingo-1 ectodomain, a module implicated in central nervous system repair inhibition. J Biol Chem (2006) 1.11
Unravelling the unusual signalling properties of the GABA(B) receptor. Biochem Pharmacol (2004) 1.09
Network-based drug discovery by integrating systems biology and computational technologies. Brief Bioinform (2012) 1.09
Poly[di-μ(3)-hy-droxy[μ(4)-5-(4-carb-oxy-phen-yl)pyridine-2-carboxyl-ato-κ(5)N,O(2):O(2'):O(4):O(4')]dicadmium]. Acta Crystallogr Sect E Struct Rep Online (2012) 1.08
Alterations in cell growth and signaling in ErbB3 binding protein-1 (Ebp1) deficient mice. BMC Cell Biol (2008) 1.08
Central nervous system agents for ischemic stroke: neuroprotection mechanisms. Cent Nerv Syst Agents Med Chem (2011) 1.06
Low bone formation in premenopausal women with idiopathic osteoporosis. J Clin Endocrinol Metab (2005) 1.06
ErbB3 binding protein 1 represses metastasis-promoting gene anterior gradient protein 2 in prostate cancer. Cancer Res (2010) 1.05
Reduced bone perfusion in osteoporosis: likely causes in an ovariectomy rat model. Radiology (2010) 1.05
Anti-inflammatory and analgesic effect of plumbagin through inhibition of nuclear factor-κB activation. J Pharmacol Exp Ther (2010) 1.04